RxDoctor Payments Data

Umesh Verma, MD

Neurology · Jackson, MINPI 1891751806

Payments from drug & device makers

$9,077in general payments, 2019–2025

Across 629 payments — averaging $14.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$1K
  • UCB, Inc.$941
  • Biogen$864
  • Teva Pharmaceuticals USA, Inc.$791
  • AbbVie$592
  • Supernus Pharmaceuticals, Inc.$547
  • plus $4K from 36 others

What the payments were for

  • Travel & lodging$100%
  • Food & beverage$9,01699%
  • Education$511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,077 in reported general payments places this provider in the 70th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$96,075
Medicare patients
429
Services billed
619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam79$125,678
VumerityDiroximel Fumarate12$103,600
Nurtec OdtRimegepant Sulfate47$82,619
CopaxoneGlatiramer Acetate11$64,172
QuliptaAtogepant22$36,787
Trokendi XrTopiramate20$29,208
AustedoDeutetrabenazine12$28,813
Emgality PenGalcanezumab-Gnlm24$17,138
Lacosamide170$15,125
LamictalLamotrigine15$15,080
Aimovig AutoinjectorErenumab-Aooe13$10,192
OngentysOpicapone12$7,638
Lamotrigine ErLamotrigine25$6,254
Carbidopa-LevodopaCarbidopa/Levodopa162$5,687
Levetiracetam156$5,625

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact$941$125,67879 claims
BiogenVumerity$864$103,60012 claims
Teva Pharmaceuticals USA, Inc.Copaxone, Austedo$791$92,98623 claims
PfizerNurtec Odt$200$82,61947 claims
AbbVieQulipta$592$36,78722 claims
Supernus Pharmaceuticals, Inc.Trokendi Xr$547$29,20820 claims
Neurocrine Biosciences, Inc.Ongentys$269$7,63812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 652 neurology providers in Michigan.

Other neurology in Jackson

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →